Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, announced the appointment of Saul Fink, Ph.D., as Chief Technology Officer. Dr. Fink will be responsible for all aspects of Q32 Bio’s chemistry, manufacturing and control (CMC)-related activities.
“We are thrilled to welcome Saul to the Q32 Bio team to take the helm of our manufacturing operations,” said Jodie Morrison, who has assumed the role of Q32’s long-term Chief Executive Officer from her previous position as acting CEO. “Saul is a proven CMC strategy and operations leader who has guided CMC and nonclinical teams across numerous therapeutic areas for both small molecule and biologic assets, at established pharmaceutical companies and nascent start-ups. With his deep leadership experience across manufacturing functions, Saul will be instrumental as we continue to drive the clinical development of our biologic therapeutics, which aim to rebalance immunity for patients with severe autoimmune and inflammatory diseases.”
Prior to joining Q32 Bio, Dr. Fink served as Senior Vice President, Pharmaceutical and Nonclinical Development at Normunity, where he led the CMC and nonclinical teams. Previously, he was Vice President of Pharmaceutical Development and Interim Lead of Nonclinical Development at Goldfinch Bio, leading manufacturing and nonclinical development of both small molecules and biologics. Prior, Dr. Fink spent 26 years at Bristol-Myers Squibb, partnering with executive management to define CMC strategy, drive business transformations and optimize manufacturing operations. Dr. Fink received his Ph.D. in Physical/Analytical Chemistry from the University of Houston, and his B.S. in Chemistry from Millersville University where he is currently a member of the Council of Trustees as part of his extensive service on not-for-profit and local government boards. He also serves as a scientific advisory board member for Intrommune Therapeutics.
SOURCE: PRNewswire